Understand the source comparison
Glutathione Dosage Protocol: Comparison of Administration Routes
Subcutaneous 200–600mg, 2–3x weekly 2–4 hours 6–8 hours ~60–70% Chronic oxidative stress models, metabolic research, sustained redox modulation Intravenous 600–2,000mg, single bolus 15–30 minutes 2–3 hours (plasma), 4–6 hours (tissue) 100% (reference) Acute de
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Subcutaneous
- 200–600mg, 2–3x weekly
- 2–4 hours
- 6–8 hours
- ~60–70%
- Chronic oxidative stress models, metabolic research, sustained redox modulation
- Intravenous
- 600–2,000mg, single bolus
- 15–30 minutes
- 2–3 hours (plasma), 4–6 hours (tissue)
- 100% (reference)
- Acute detoxification, ischemia-reperfusion injury, high-dose intervention trials
- Oral
- 500–1,000mg daily
- Variable, 1–3 hours
- 3–5 hours
- ~10–20%
- Limited to gut-focused research, not suitable for systemic GSH studies
- Intramuscular
- 200–400mg, 2x weekly
- 1–2 hours
- 5–7 hours
- ~50–60%
- Rarely used; no bioavailability advantage over subcutaneous
- Bottom Line
- Subcutaneous 400–600mg twice weekly delivers sustained plasma elevation with minimal administration burden, making it the preferred route for research models examining chronic glutathione effects on cellular redox status, immune function, and metabolic endpoints. IV remains the gold standard for acute intervention but requires technical expertise and controlled settings.
- Subcutaneous administration has become the standard in contemporary glutathione research because it balances bioavailability with practical implementation. The slower absorption profile from subcutaneous depots avoids the rapid oxidation that occurs when high concentrations of GSH hit the plasma simultaneously, as happens with IV bolus. Tissue uptake mechanisms. Primarily sodium-dependent transporters in kidney, liver, and gut epithelium. Function optimally with sustained moderate concentrations rather than acute spikes.